共 50 条
- [41] The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER plus breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 69 - 79Bean, Jennifer R.Hosford, Sarah R.Symonds, Lynn K.Owens, PhilipDillon, Lloye M.Yang, WeiShee, KevinSchwartz, Gary N.Marotti, Jonathan D.Muller, Kristen E.Rosenkranz, Kari M.Barth, Richard J.Chen, Vivian S.Agarwal, Veena R.Miller, Todd W.
- [42] Investigating anti-tumor immunity with CDK4/6 inhibition in triple negative breast cancer.CANCER RESEARCH, 2021, 81 (13)Guo, QiuchenSpasic, MilosGoreczny, GregoryMaynard, AdamMcAllister, Sandra
- [43] Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel CombinationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E2 - E2Chowdhary, M.Sen, N.Chowdhary, A.Usha, L.Cobleigh, M.Wang, D.Patel, K.Barry, P. N., Jr.Rao, R.
- [44] An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer modelsEUROPEAN JOURNAL OF CANCER, 2018, 103 : E39 - E40Hu, S.Marineau, J.Bradley, M.Hamman, K.Alnemy, S.Smith, D.Carulli, J.Chuaqui, C.
- [45] PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER plus /Rb-deficient breast cancerCANCER RESEARCH, 2023, 83 (07)Lin, Chang-ChingChang, Tsung-ChengWang, YunguanZhang, YanfengLemoff, AndrewFang, Yisheng V.Zhang, HeYe, DanSoria-Bretones, IsabelServetto, AlbertoLee, Kyung-MinLuo, XuemeiOtto, Joseph J.Akamatsu, HiroakiCescon, David W.Xu, LinXie, YangMendell, Joshua T.Hanker, Ariella B.Arteaga, Carlos L.
- [46] Reparixin, CXCR1/2 inhibitor in combination with CDK4/6 inhibitors attenuates endocrine resistant breast cancer growth and metastasisCANCER RESEARCH, 2022, 82 (12)Pandithar, SnehaReff, OliviaJin, Kideok
- [47] Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitorCANCER COMMUNICATIONS, 2023, 43 (06) : 720 - 725Karimi, LeenaAlves, Carla L.Terp, Mikkel G.Tuttolomondo, MartinaPortman, NeilEhmsen, SidseJohansen, Lene E.Bak, MartinLim, ElgeneDitzel, Henrik J.
- [48] Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancersCANCER RESEARCH, 2022, 82 (12)Zhou, FengYang, GuimeiTang, FengZhang, YanYang, WenqingXue, LitingChen, PingTang, Renhong
- [49] Anti-tumor activity of elacestrant (RAD1901) in combination with alpelisib (BYL-719) in patient-derived xenograft models of ER plus breast cancerCANCER RESEARCH, 2018, 78 (04)Sankaran, BanuGarner, FionaHattersley, GaryPurandare, DineshBihani, Teeru
- [50] Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (vol 12, 5112, 2021)NATURE COMMUNICATIONS, 2021, 12 (01)Alves, Carla L.Ehmsen, SidseTerp, Mikkel G.Portman, NeilTuttolomondo, MartinaGammelgaard, Odd L.Hundebol, Monique F.Kaminska, KamilaJohansen, Lene E.Bak, MartinHoneth, GabriellaBosch, AnaLim, ElgeneDitzel, Henrik J.